Interchangeability and diagnostic accuracy of two assays for total and free prostate-specific antigen: Two not always related items

International Journal of Biological Markers

Volumn 22, Issue 2, 2007, Pages 154-158

  Dittadi, Ruggero ^a   Franceschini, R ^b   Fortunato, A ^c   Zancan, M ^b   Barichello, M ^d   Tasca, A ^c   Giavarina, D ^c   Peloso, L ^b   Soffiati, G ^c   Gion, M ^e  

^a Regional General Hospital   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d General Regional Hospital   (Italy)

^e IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Diagnosis; Immunoassays; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

EID: 34447325342     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5070     Document Type: Article

References (20)

1. Semjonow A, De Angelis G, Oberpenning F, Schmid HP, Brandt B, Hertle L. The clinical impact of different assays for prostate specific antigen. BJU Int 2000; 86: 590-7.
2. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001; 88: 545-50.
3. Oberpenning F, Weining C, Brandt B, et al. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls. Eur Urol 2002; 42: 577-82.
4. Gray MA, Cooke RR, Weinstein P, Nacey JN. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000. Ann Clin Biochem 2004; 41: 207-12.
5. Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 2004; 50: 1012-6.
6. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5-12.
7. Jung K, Elgeti U, Lein M, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62.
8. Lein M, Jung K, Elgeti U, et al. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 2001; 39: 57-64.
9. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57: 1105-11.
10. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/ total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165: 1549-53.
11. Brawer MK. Clinical usefulness of assays for complexed prostate-specific antigen. Urol Clin North Am 2002; 29: 193-203, xi.
12. Ciatto S, Rubeca T, Franceschini R, et al. On the clinical usefulness of the free-to-total prostate-specific antigen ratio. Int J Biol Markers 2006; 21: 1-5.
13. Morote J, Trilla E, Esquena S, et al. Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer. Int J Biol Markers 2002; 17: 239-43.
14. Mione R, Barioli P, Barichello M, et al. Prostate cancer probability after total PSA and percent free PSA determination. Int J Biol Markers 1998; 13: 77-86.
15. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21: 709-20.
16. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8: 135-60.
17. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alphal-antichymotrypsin complex together with free or total PSA. Clin Chem 2003; 49: 97-103.
18. Link RE, Shariat SF, Nguyen CV, et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 2004; 171: 2234-8.
19. Schambeck CM, Schmeller N, Stieber P, et al. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 1995; 46: 195-9.
20. Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 2006; 52: 59-64.